Gilead Sciences, Inc.
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 11/3097% above fair value
$167.47−2.86 (-1.68%)
Close on Nov 3, 2026Market cap $207.66BP/E –Yield 1.89%
Gilead Sciences GAAP effective tax rate: 13.1% in FY2025, down 17.4 pts from a year earlier.
Latest, FY2025
13.1%
Period ended Dec 31, 2025
Change on a year earlier
-17.4 pts
30.5% in FY2024
History
12 years
Since FY2014
Sources
11
Documents cited below
Where the FY2025 figure comes from
“|| GAAP effective tax rate | (5.0) | % | 17.8 | % | 13.1 | % | 30.5 | %”
Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Reported in Form 10-Q / 10-K & Form 8-K.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Gilead Sciences GAAP effective tax rate (%), annual FY2014–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/gaap-tax-rate-pct
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.
See a number that looks wrong?